EN DE
Watch Enimmune corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Enimmune corporation (6564) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Enimmune corporation stock TWD 9.57, price TWD 14.90, that is 35.8% below the price, quality 36 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006564008

EC Enimmune corporation logo Thin data Nov 10, 2026

Enimmune corporation

6564 · TWO
Weakest Setup

Our calculation puts a fair price 36% below what the stock costs today.

Low debt
Revenue last quarter +23% vs. a year ago.
Fair value 9.57 TWD · Strongly overvalued
Quality 36/100
Weak Growth (revenue 3y −36.5 %/yr in TWD)
Negative free cash flow
Trails peers (1/9)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Enimmune corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

21.90 TWD 13.75 TWD Fair Value 9.57 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

11‑month range 13.75 TWD – 21.90 TWD · fair‑value band 7.17 TWD – 11.96 TWD · the 14.90 TWD price screens above the 9.57 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Enimmune in your weekly email

Every Wednesday you see whether Enimmune is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services.

Show moreShow less

It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, which is in pre-clinical stage for the treatment of Japanese encephalitis virus; EV71+CA16 bivalent vaccine, which is in research stage for the treatment of hand-foot-mouth disease caused by Coxsackie A virus and enterovirus 71; and Anti-RBD monoclonal antibody, a murine monoclonal antibody for the recognition of receptor binding domain of the SARS-CoV-2 spike protein.

The company was founded in 2014 and is based in Taipei, Taiwan. Enimmune Corporation is a subsidiary of Adimmune Corporation.

Stock analysis

Enimmune corporation (6564) currently trades at 14.90 TWD, while our estimate is 9.57 TWD, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 7.17 TWD (bear) to 11.96 TWD (bull), the price of 14.90 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Enimmune corporation reported revenue of 48.2M TWD in FY2025 versus 110M TWD in FY2021, a compound −18.6%/yr. Reported net income was −164M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $32.7M) Micro · P/S ratio 20.2 · EPS (TTM) −1.67 TWD · Return on equity −74.5% · Return on assets (EBIT) −29.7% (5-year average) · Operating margin −175% · Revenue (TTM) 53.4M TWD · Revenue growth (YoY) +23.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −36%, 6564 screens richer than that median.

Fair Value

Bear 7.17 TWD Fair Value 9.57 TWD Bull 11.96 TWD
Price 14.90 TWD · Downside -35.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 56
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−361.6% (2020) → −387.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6564 screens overvalued: fair value 36% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Enimmune corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −35.8% · Below median
Profitability
Return on assets −36.0% · Below median
Operating margin (12 months) −174.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.2% · Above median
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.18× · Priciest 25%
P/S (12 months) 20.11× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6564
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6564
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6564
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6564
argenx SE ARGX $971.55 $908.40 −7% vs 6564
CSL Limited CSL A$201.68 A$181.40 −10% vs 6564
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6564
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6564
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6564
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6564

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Enimmune corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Enimmune corporation Fair Value". https://www.fairvalue-calculator.com/stock/6564

Frequently asked questions

Is Enimmune corporation (6564) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 9.57 TWD versus a price of 14.90 TWD, about 36% lower (overvalued).
What is the fair value of 6564?
Our estimate for Enimmune corporation is 9.57 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 14.90 TWD.
What is the quality score of 6564?
Enimmune corporation has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enimmune corporation (6564)?
Our calculated price target is the estimate of 9.57 TWD (as of Nov 10, 2026). Cautious scenario 7.17 TWD, optimistic scenario 11.96 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Enimmune corporation stock forecast for 2026?
Our estimate puts fair value at 9.57 TWD, about 36% lower versus a price of 14.90 TWD (overvalued). Cautious scenario 7.17 TWD, optimistic scenario 11.96 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Enimmune corporation (6564)?
Enimmune corporation reported trailing-twelve-month revenue of about 53.4M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Enimmune corporation (6564)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enimmune corporation it is 9.57 TWD per share (as of Nov 10, 2026), against a price of 14.90 TWD.
Is Enimmune corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6564 trades above its calculated fair value: price 14.90 TWD, fair value 9.57 TWD, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6564?
No. The price is what the market pays today (14.90 TWD); the fair value is what the company's own numbers justify (9.57 TWD). For Enimmune corporation the two are 5.33 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Enimmune corporation worth?
The market values Enimmune corporation at about 1.1B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 14.90 TWD; our models calculate a fair value of 9.57 TWD per share.
What do the bullish and bearish scenarios say about 6564?
Our models span a range for Enimmune corporation: cautious scenario 7.17 TWD, base 9.57 TWD, optimistic 11.96 TWD per share (as of Nov 10, 2026, price 14.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enimmune corporation (6564)?
Balance-sheet figures for Enimmune corporation (as of Nov 10, 2026): return on equity −74.5%, debt of 0.19 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 6564 from its 52-week high?
Enimmune corporation trades at 14.90 TWD, about 32% below its 52-week high of 21.90 TWD and 8% above the low of 13.75 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 9.57 TWD is for.
Which stocks are comparable to Enimmune corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enimmune corporation stock attractive at the current price?
The data as of Nov 10, 2026: price 14.90 TWD, calculated fair value 9.57 TWD (−36%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Enimmune corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enimmune corporation (6564)?
The closing price on Nov 10, 2026 was 14.90 TWD. Our estimate is 9.57 TWD, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enimmune corporation right now?
The price sits above even our optimistic bull case (11.96 TWD). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Enimmune corporation

How large is the market capitalisation of Enimmune corporation (6564)?
The market capitalisation of Enimmune corporation is 1.1B TWD (≈ $32.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enimmune corporation (6564)?
The price-to-sales ratio of Enimmune corporation is 20.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enimmune corporation (6564)?
Earnings per share at Enimmune corporation are −1.67 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Enimmune corporation (6564)?
The return on equity (ROE) of Enimmune corporation is −74.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enimmune corporation (6564)?
On an EBIT basis the return on assets of Enimmune corporation is −29.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Enimmune corporation (6564)?
The operating margin of Enimmune corporation is −175% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Enimmune corporation (6564)?
Revenue at Enimmune corporation is growing +23.2% versus a year earlier (3y avg −36.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Enimmune corporation (6564) generate?
The free cash flow of Enimmune corporation is −147M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Enimmune corporation (6564) hold?
Enimmune corporation holds more cash than debt, 377M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Enimmune corporation in the live analysis

One click puts Enimmune corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.